Molecular Profiling: Getting to Know Your Tumor
Dr. Johanna Bendell explains the value of molecular profiling. It can indicate which type of chemotherapy will be more successful on your tumor.
Immunotherapy for Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs…
Keytruda Runner-Up for Science Breakthrough of the Year
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine’s Breakthrough of the year.
Chemotherapy, Immunotherapy, and Radiation for Locally Advanced Pancreatic Cancer
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
Presurgical Treatment for Pancreatic Cancer That Is Removable
A clinical trial looks at immunotherapy plus vitamin D plus standard chemotherapy before surgery to remove pancreatic cancer.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency
Support from the Lustgarten Foundation was critical to the success of the clinical trial that demonstrated the efficacy of pembrolizumab…
Immunotherapy to Help Shrink Pancreatic Tumors for Surgery
Researchers are looking at adding checkpoint drugs–a type of immunotherapy–to standard chemoradiation to shrink pancreatic cancer for surgery.
